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Background: An updated economic evaluation was conducted to compare the cost-effectiveness of the four
tumour necrosis factor (TNF)-α inhibitors adalimumab, etanercept, golimumab and infliximab in active, progressive
psoriatic arthritis (PsA) where response to standard treatment has been inadequate.
Methods: A systematic review was conducted to identify relevant, recently published studies and the new trial data
were synthesised, via a Bayesian network meta-analysis (NMA), to estimate the relative efficacy of the TNF-α inhibitors
in terms of Psoriatic Arthritis Response Criteria (PsARC) response, Health Assessment Questionnaire (HAQ) scores and
Psoriasis Area and Severity Index (PASI). A previously developed economic model was updated with the new
meta-analysis results and current cost data. The model was adapted to delineate patients by PASI 50%, 75% and
90% response rates to differentiate between psoriasis outcomes.
Results: All four licensed TNF-α inhibitors were significantly more effective than placebo in achieving PsARC response
in patients with active PsA. Adalimumab, etanercept and infliximab were significantly more effective than placebo
in improving HAQ scores in patients who had achieved a PsARC response and in improving HAQ scores in PsARC
non-responders. In an analysis using 1,000 model simulations, on average etanercept was the most cost-effective treatment
and, at the National Institute for Health and Care Excellence willingness-to-pay threshold of between £20,000 to £30,000,
etanercept is the preferred option.
Conclusions: The economic analysis agrees with the conclusions from the previous models, in that biologics are shown to
be cost-effective for treating patients with active PsA compared with the conventional management strategy. In particular,
etanercept is cost-effective compared with the other biologic treatments.Background
Psoriatic arthritis (PsA) is a chronic systemic inflamma-
tory disease characterised by joint involvement and several
heterogeneous extra-articular manifestations, including
enthesitis, dactylitis and dermatological involvement of
the skin and nails (1). The broad involvement of articular
and non-articular sites can have a significant impact on
patients’ function and quality of life [2]. The presentation
of PsA has been categorised into five overlapping clinical
patterns; oligoarthritis (22% to 37% of patients); polyarthritis* Correspondence: stephen.mitchell@abacusint.com
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reproduction in any medium, provided the or(36% to 41% of patients); arthritis of distal interphalangeal
joints (up to 20% of patients); spondylitis (7% to 23% of
patients); and arthritis mutilans (approximately 4%) [3,4].
The prevalence of PsA is greater among psoriasis pa-
tients, with a prevalence rate spanning a wide range from
7% to 26% [5]. Around seventy per cent of PsA patients
develop joint complications usually around ten years after
developing skin symptoms, whereas, 10-15% of patients
suffer from joint damage before developing psoriasis, and
in the remaining 10-15% of patients, these symptoms
may manifest simultaneously [6].
There are a number of published recommendations for
the management of PsA [7,8]. Treatment is dependent on
the type and severity of the skin and joint involvement. Pa-
tients with mild-to-moderate PsA are frequently givenl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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intra-articular steroid injections. Patients with more severe
PsA and persistent arthritis not responding to NSAIDs
are treated with disease-modifying anti-rheumatic drug
(DMARD) therapy. Methotrexate, sulphasalazine and
cyclosporine-A are the commonly used DMARDs [9].
More recently, newer treatments targeting the inflam-
matory cascade and preventing disease progression have
been introduced including tumour necrosis factor (TNF)-
α inhibitors. These drugs are used as monotherapy or in
combination with the traditional nonbiologic DMARDs
such as methotrexate. The combination regimen is used
in patients with severe disease or with ongoing joint
damage and disease progression [6]. While there is
evidence to suggest that treatment with concomitant
methotrexate is beneficial compared with TNF-α
monotherapy (resulting from fewer withdrawals due
to adverse events) [10], this has not been a universal
finding [11].
There are currently no head-to-head randomised con-
trolled trials (RCTs) comparing the TNF-α inhibitors to
each other and therefore attempts to compare the rela-
tive efficacy and safety of these agents have relied upon
a qualitative review of the published evidence or meta-
analytic techniques [12]. A recently published meta-
analysis assessing the relative efficacy of the currently
available TNF-α inhibitors concluded that etanercept
was the most efficacious treatment (as measured by
American College of Rheumatology (ACR) response)
compared with infliximab and adalimumab [13]. RCT
data are also available for the TNF-α inhibitor golimu-
mab [14] which has recently been recommended by the
National Institute for Health and Care Excellence
(NICE) as an option for the treatment of active and pro-
gressive PsA in adults, in the UK [15]. An economic
evaluation developed for the NICE review concluded
that etanercept, infliximab and adalimumab are cost-
effective versus palliative care [16,17]. However, it is un-
clear how cost-effective golimumab is compared with
palliative care (conventional management strategy) and
head-to-head with these three biologics.
Therefore, this paper presents a new economic evalu-
ation supported by an updated systematic review and meta-
analysis that included recent data for golimumab, the ob-
jective being to determine the relative cost-effectiveness
of all UK licensed biological disease-modifying anti-
rheumatic drugs (bDMARDs) for the treatment of active,
progressive PsA in patients with inadequate response to
previous DMARDs. The paper presents the results from
the updated meta-analysis for all clinical measures of
efficacy used in the economic model (note that other
clinical measures such as ACR response are reported
elsewhere [18]). The meta-analysis results were used in a
revised economic model which updates the previous NICEmodels [16,17] to provide a cost-effectiveness comparison
of all four TNF-α inhibitors adalimumab, etanercept, goli-
mumab and infliximab.
Methods
A comprehensive systematic review was conducted to
identify RCTs of bDMARDs for the treatment of people
with active PsA (defined globally as one or more tender
and inflamed joint and/or tender enthesis point and/or
dactylitic digit and/or inflammatory back pain [8]) who
have responded inadequately to previous DMARDs.
Structured literature searches were conducted for the
following databases (accessed October 31st 2011): The
Cochrane Library (including Cochrane Reviews, the
Database of Abstracts of Reviews of Effects (DARE),
the Cochrane Central Register of Controlled Trials
(CENTRAL), the Health Technology Assessment Database
(HTA)), Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid MEDLINE(R) (1948 to
present), and OVID EMBASE (1980 to present). Search
terms included those for the disease (‘psoria* adj arthrit*’),
interventions (‘DMARD’ or etanercept or infliximab or
adalimumab or golimumab) and study type (randomi?ed
controlled study). In addition the following conference
proceedings were hand-searched (2008–2011 inclusive):
World Psoriasis and Psoriatic Arthritis Conference, ACR,
European League against Rheumatism (EULAR), British
Society for Rheumatology (BSR). Reference lists of in-
cluded studies and previously published systematic re-
views were also examined for relevant citations. Studies
(full publications or conference abstracts in the absence
of a full publication) were included in the systematic re-
view if they met the pre-defined inclusion criteria (see
Additional file 1).
Potentially relevant studies (based on abstract/title)
were examined in full by two independent reviewers.
Relevant outcome data were extracted by two indepen-
dent reviewers and any disputes resolved by consensus.
The quality of the included RCTs was assessed accor-
ding to the methodology checklist detailed in the NICE
Guidelines Manual 2009 [19,20]. In brief, this assesses
the likelihood of selection, attrition, detection, and per-
formance bias.
The methodology for the meta-analysis was as per
Rodgers et al., 2011 [16], and the recommended methods
published by the NICE Decision Support Unit [21]. The
following outcomes were evaluated to assess the relative ef-
ficacy of the bDMARDs: Psoriatic Arthritis Response
Criteria (PsARC) response; change in Health Assessment
Questionnaire (HAQ) score from baseline (change in HAQ
score for all patients; HAQ score conditional on PsARC
response); Psoriasis Area and Severity Index (PASI).
The analysis of the PsARC and PASI dichotomous (pa-
tient count) outcomes was conducted on an intent-to-treat
Figure 1 Markov model structure.
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standard error in mean change were used. An ordered
multinomial analysis of PASI score at follow-up was con-
ducted based on the number of patients in four PASI re-
sponse categories: PASI score improvement of 0% to 50%,
PASI score improvement of 50% to 75%, PASI score im-
provement of 75% to 90%, and PASI score improvement of
90% to 100%. An ordered multinomial model makes more
efficient use of categorical data than a binomial analysis of
each category separately. Note that in the clinical trials,
PASI scores at follow-up were reported for patients who
had ≥3% body surface area (BSA) involvement at baseline
or a PASI score ≥2.5 at baseline.
Study inclusion criteria allowed the inclusion of out-
comes measured after at least 12 weeks of follow-up,
since clinical response should have occurred by that
point, and outcomes reported for up to 24 weeks of
follow-up. Data from the 12–16 week follow-up was
used in the basecase as outcomes at this time point are
reported for most studies (and in some studies this was
the pre-crossover follow-up point). In studies with an
early escape design, the 24 week data were included pro-
vided the pre-crossover observation was carried forward.
A Bayesian network meta-analysis (NMA) using unin-
formative priors was conducted in WinBUGS version
1.4.1. [22-24]. Whereas standard meta-analyses evaluate
the relative efficacy of just two treatments based on
head-to-head trials only, NMA comprises an extension
of these methods in which treatment effects are calcu-
lated for a network of treatments [25-27]. Hence NMAs
estimate the relative efficacy of each treatment in the
network compared with all other treatments. An NMA
builds on the principles of indirect comparisons whilst
preserving trial randomisation [28-30].
For the analysis of HAQ conditional on PsARC response,
it was assumed that TNF-α inhibitors have different treat-
ment effects conditional on PsARC response. For the ana-
lysis of ordered PASI response thresholds, a number of
assumptions were made to facilitate modelling: a common-
effects model was used to estimate the baseline response
estimated using data from placebo non-responders (i.e.
those receiving placebo and not achieving PASI 50); com-
mon effects were assumed for each treatment (etanercept,
golimumab, infliximab and adalimumab); thresholds were
assumed to be fixed across trials and the baseline latent
variable was assumed fixed.
For full details on the methodology the reader is referred
to Rodgers et al., 2011 [16].
The economic model is a Markov cohort model using
3-month cycles, and is based on a previously published
model structure [16,17]. The original model was used to
evaluate the cost-effectiveness of etanercept, adalimumab,
infliximab and palliative care (conventional management
strategy). This structure was adapted to include additionalPASI response (PASI 50 and PASI 90) levels to provide
more sensitivity to the psoriasis element of the disease and
the cost and efficacy data were updated to include the re-
cent evidence for golimumab. Model methods and as-
sumptions are consistent with the original model [16,17].
For biologic treatment, the PsARC response criterion is
used to determine a response in the first three months.
Following this initial assessment the impact on the two ele-
ments of PsA, arthritis and psoriasis, are assessed using the
HAQ and PASI respectively. The change in HAQ and PASI
scores are assumed to be relative to their baseline values
(assumed to be 1.05 and 7.5, respectively as per Bojke et al.,
2011 [17]). Patients on palliative care are assumed to follow
the natural history of HAQ and PASI [16,17].
The model structure as shown in Figure 1 follows a
cohort of patients with PsA as follows:
 Initial 3 month period: the probability of a PsARC
response is used to determine the proportion of
patients who enter the subsequent model pathways.
 If PsARC response is achieved, patients remain on
treatment and it is assumed the gain in HAQ is
maintained while biologic therapy is maintained [16,17].
 If PsARC response is not achieved, patients revert to
the conventional management strategy and it is
assumed that the rebound is equal to gain, after
which natural HAQ progression is assumed.
 Subsequent follow-up: modelled as three-month
cycles (up to 159 cycles = 40 years total follow-up).
 During each subsequent period there is a probability
of withdrawal from therapy which is assumed to be
the same for all treatments [16,17].
 Quality-adjusted life years (QALYs) for each
treatment are derived by mapping the estimated
HAQ and PASI scores onto utilities using the same
equation as for the other models (Expected Utility =
0.897-0.298 x HAQ −0.004 x PASI [(SE) (0.006)
(0.006) (0.0003)]) [16,17].
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Bojke et al., 2011 model [17] in a number of elements.
The most significant regards the psoriasis element of the
model. Where the previously published model [17] uses
PASI 75 only, the new model delineates PASI further by
using PASI 50, 75 and 90 response rates derived from
the meta-analysis. This makes the model more sensitive
to differences in psoriasis outcomes. Patients continue
on biologic treatment even if they do not meet a given
PASI response level. Patients will remain on treatment
for as long as a PsARC response is sustained and receive
a proportionate gain in PASI from baseline over the du-
ration of this period (see Rodgers et al., 2011 [16] for
further detail).
Rodgers et al., 2011 indicated that PsARC and PASI
response may not be independent [16]. Hence the rela-
tionship between PsARC and PASI was taken from the
Rodgers et al., 2011 HTA publication [16] as the as-
sumptions regarding the PsARC and PASI relationship
were not explicit in the Bojke et al., 2011 paper [17].
Furthermore the proportion of males with PsA entering
the model was also unclear and thus we assumed a
50:50 split. This assumption only affects the all-cause
general mortality calculation which was applied to all
treatments and was estimated from UK life tables [31].
All drug [32] and attendance costs were updated to
2012, while resource costs and direct costs were uplifted
to 2011 using the Hospital and Community Health
Services Index (HCHS) [33] and the annual discount rate
is 3.5% for both costs and QALYs [20]. Dosage was consis-
tent with current guidance (BNF, 64): infliximab (in
combination with methotrexate) dosage is 5 mg/kg and
the model assumes an average weight of 75 kg. TheTable 1 Economic model drug cost data and other economic
Drug cost, £+ ETN INF
First 3 months 2323.75 5043.21
Months 4-6 2323.75 2693.34
Subsequent 3 months 2323.75 2693.34
Other data
Change in cost for 1 U change in HAQ
Three-month cost for mild-to-moderate psoriasis if uncontrolled by biologics
Three-month cost for psoriasis in remission
Change in HAQ while on treatment per 3-month period
Change in HAQ while not on treatment per 3-month period
Log withdrawal rate from biologics per year
Probability of PsARC response on placebo
Change in HAQ given a PsARC response on placebo
Probability of PASI 75 response on placebo
+All costs inflated to 2010/11 values (£’s); ADA, Adalimumab 40 mg/2 weeks; BSR, B
5 mg/kg/8 weeks; GOL, Golimumab 50 kg/4 weeks; HAQ, health assessment questio
Severity Index; PSA, distribution used in probabilistic sensitivity analysis.updated cost data and other data in the model are shown
in Table 1. A Monte Carlo simulation methodology was
used for a probabilistic sensitivity analysis. All parameters
in the model were characterised by probabilistic distri-
butions as described in Bojke et al., 2011 [17] (see Table 1).
Results and discussion
A total of 2,099 potentially relevant citations were iden-
tified for inclusion in the systematic review on the basis
of the database search, of which 2,036 were excluded on
the basis of title or abstract (see Additional file 2). On
re-application of the review inclusion criteria to the 63
full-text papers, a further 38 were excluded. Five add-
itional publications were identified as a result of search-
ing conference proceedings and the grey literature.
Therefore 30 publications detailing 12 RCTs [14,39-49]
met the inclusion criteria and were included in the sys-
tematic review.
On completion of the data extraction, a feasibility
assessment was conducted to assess a priori which
studies were sufficiently homogenous to be combined
in a robust meta-analysis. On review of the 12 studies
with regard to study design, inclusion criteria, treatment reg-
imens and reported outcomes, five studies [41,42,45,46,49]
were excluded for either having a short follow-up time [49],
not having a placebo arm required for inclusion in the
network analysis [41,42], or inclusion criteria [45,46], lea-
ving seven studies [14,39,40,43,44,47,48] in the potential
evidence network.
 Two studies examining adalimumab 40 mg every
other week (n = 204) versus placebo (n = 211)
[47,48]model data
ADA GOL PSA Ref
2288.91 2288.91 Normal BSR guidelines [34] and MIMS [35]
2288.91 2288.91
2288.91 2288.91
Mean SE PSA Ref
106.5 69.3 Normal Kobelt 2002 [36]
205.2 9.3 Normal DoH 2007/2008 [37]
16.5 1 Normal Hartman 2003 [38]
0 0.02 Normal Bojke 2011 [17] (expert elicitation)
0.018 0.007 Gamma Bojke 2011 [17] (NOAR estimate)
−1.823 0.2044 Normal Bojke 2011 [17] (Registers)
0.249 0.0384 Beta Bojke 2011 [17] (Evidence synthesis)
−0.2436 0.04746 Normal Bojke 2011 [17] (Evidence synthesis)
0.044 0.009 Beta Bojke 2011 [17] (Evidence synthesis)
ritish Society of Rheumatology; ETN, Etanercept 2×25 mg/week; INF, Infliximab
nnaire; PsARC, Psoriatic Arthritis Response Criteria; PASI, Psoriasis Area and
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weekly (n = 131) versus placebo (n = 134) [39,40]
 A single study examining golimumab 50 mg (n = 146)
every 4 weeks versus placebo (n = 113) plus a third
unlicensed arm (golimumab 100 mg every 4 weeks:
n = 146) [14]
 Two studies examining infliximab 5 mg/kg (n = 152)
versus placebo (n = 152) [43,44]
The degree of clinical heterogeneity between the seven
included trials in terms of joint and skin disease severity
and functional status was reasonable and therefore the de-
gree of exchangeability between the trials for the purposes
of the meta-analysis was good. The seven studies were gen-
erally of good quality: randomisation, blinding, concealment
of allocation and intention-to-treat analyses were adequate
in most trials. In order to conduct the meta-analysis for the
HAQ outcome, additional data were also extracted from
two secondary publications (Rodgers et al., 2011 [16] and
Cummins et al., 2011 [50]). See the online appendix for a
summary of the studies (Additional file 3) and the data ex-
tracted for the meta-analysis (Additional files 4 and 5).
Table 2 summarises the NMA results which were used
in the economic evaluation alongside a comparison with
the results from the NMA by Rodgers et al., 2011 [16].
(Note that results for the ACR outcomes which are not
used in the economic model are reported in Spurden
et al., 2012 [18]).
Similar results were obtained in the sensitivity analysis
using data up to week 24 (not shown). All four licensedTable 2 Results of fixed-effect network meta-analysis and com
et al., 2011 [16]
Placebo Ada
40 m
PsARC response: Odds ratio versus placebo OR (95% CrI) NA 4.28
Probability (95% CrI)+ 0.26 (0.22, 0.29) 0.59




WMD versus placebo non-responders |
PsARC responders (95% CrI)*
−0.26 (−0.32, -0.21)† −0.4
Comparison with Rodgers 2011 [12] −0.24 (−0.34, -0.15)† −0.4
WMD versus placebo non-responders |
PsARC non-responders (95% CrI)*
NA −0.1
Comparison with Rodgers 2011 [12] NA −0.1
PASI50 Probability (95% CrI)+ 0.12 (0.09, 0.16) 0.71
Comparison with Rodgers 2011 [12] 0.13 (0.09,0.18) 0.74
PASI75 Probability (95% CrI)+ 0.05 (0.03, 0.07) 0.47
Comparison with Rodgers 2011 [12] 0.04 (0.03,0.07) 0.48
PASI90 Probability (95% CrI)+ 0.02 (0.01, 0.03) 0.24
Comparison with Rodgers 2011 [12] 0.02 (0.01,0.03) 0.26
CrI, credible interval (Bayesian probability interval); HAQ, health assessment questio
Response Criteria; PASI, Psoriasis Area and Severity Index; WMD, weighted mean dif
results were used in the economic model; the probabilistic sensitivity analysis used
probabilistic sensitivity analysis used a normal distribution. Results for direct, fixed-e
and 8.TNF-α inhibitors were significantly more effective than
placebo in achieving PsARC response in patients with
active PsA (Table 2, Additional file 9). Etanercept and
infliximab were significantly more effective than placebo
in improving HAQ scores (Additional file 10). Golimu-
mab was not significantly better than placebo in impro-
ving HAQ scores [18].
For the change in HAQ conditional on PsARC response,
adalimumab, etanercept and infliximab were significantly
more effective than placebo in improving HAQ scores in
patients who had achieved a PsARC response but also in
improving HAQ scores in PsARC non-responders (Table 2.
Additional file 11). Golimumab was not significantly better
than placebo in improving HAQ scores in patients who
had achieved a PsARC response (the 95% CrI for golimu-
mab PsARC responders overlaps the 95% CrI for placebo
PsARC responders, see Table 2).
The meta-analysis for conditional change in HAQ based
on PsARC response produced similar results to the meta-
analysis reported in Rodgers et al., 2011 [16] which
assessed three of the TNF-α inhibitors. The Rodgers
NMA did not report the relative treatment effects for the
PsARC analysis but instead reported the absolute prob-
ability of PsARC, which requires an estimate of the under-
lying background response (placebo response) as well as
the treatment effects relative to placebo. Table 2 shows a
comparison of the absolute probability of PsARC reported
in Rodgers et al., 2011 versus the corresponding results
from our NMA. The PsARC analysis results were sensitive









(2.83, 6.57)† 9.97 (5.95, 17.08)† 10.33 (5.84, 19.04)† 7.74 (4.5, 13.67)†
(0.48, 0.70) 0.77 (0.66, 0.86) 0.78 (0.66, 0.87) 0.73 (0.60, 0.83)
(0.44, 0.71) 0.80 (0.67, 0.89) NA 0.71 (0.57, 0.83)
9 (−0.58, -0.40)† −0.66 (−0.77, -0.55)† −0.44 (−0.59, -0.29)† −0.64 (−0.77, -0.51)†
8 (−0.60, -0.35)† −0.66 (−0.79, -0.52)† NA −0.63 (−0.81, -0.46)†
4 (−0.24, -0.03)† −0.20 (−0.31, -0.08)† −0.06 (−0.18, 0.06) −0.20 (−0.35, -0.050)†
3 (−0.26, -0.00)† −0.19 (−0.33, -0.06)† NA −0.19 (−0.381, 0.00)
(0.51, 0.86) 0.90 (0.80, 0.96) 0.71 (0.50, 0.87) 0.40 (0.16, 0.73)
(0.55,0.88) 0.91 (0.82,0.97) NA 0.40 (0.24,0.59)
(0.27, 0.68) 0.77 (0.59, 0.89) 0.46 (0.26, 0.70) 0.19 (0.06, 0.49)
(0.28,0.69) 0.77 (0.59,0.90) NA 0.18 (0.09,0.31)
(0.12, 0.44) 0.54 (0.34, 0.75) 0.23 (0.11, 0.46) 0.08 (0.02, 0.26)
(0.12,0.45) 0.56 (0.35,0.77) NA 0.07 (0.03,0.15)
nnaire; NMA, network meta-analysis; OR, odds ratio; PsARC, Psoriatic Arthritis
ferences; NA, not applicable †significant result based on 95% CrI. +Average
a beta distribution. *Average results were used in the economic model; the
ffect meta analysis for PASI 70/75/90 are reported in Additional files 6, 7
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16 week data reported in the publication (analysis not
shown). This affected both the underlying background re-
sponse and the relative effect of infliximab. However, this
did not alter the overall ranking of the TNF-α inhibitors.
An incremental analysis was conducted where treat-
ments are listed in order of clinical efficacy and the in-
cremental cost-effectiveness ratio (ICER = ratio of
difference in costs and difference in QALYs) of each
intervention is calculated by comparing it to the next
most effective intervention (see Table 3). Based on this
incremental analysis golimumab was dominated by eta-
nercept (etanercept costs less and is more effective than
golimumab); adalimumab was extendedly dominated by
etanercept (ICER is greater than that of the more effec-
tive intervention); etanercept was cost-effective (based
on an ICER < £20,000- £30,000) compared with the con-
ventional management strategy and infliximab was not
cost-effective compared with etanercept. These findings
are similar to those reached by Bojke et al., 2011 [17].
Probabilistic sensitivity analysis was undertaken to
evaluate the robustness of the deterministic results and
compared all the treatments. Figure 2, upper panel
shows the incremental cost and QALYs of etanercept
versus other treatments and Figure 2, lower panel shows
the proportion of simulations with the highest net mon-
etary benefit (NMB) based on willingness-to-pay (WTP,
NMB= (QALYs*WTP – cost) at different WTP thresholds.
In an analysis using 1,000 model simulations (40 year
model), on average, etanercept was the most cost-effective
treatment and, at a WTP threshold of between £20,000 and
£70,000, etanercept is the preferred option. When consider-
ing the NICE WTP threshold of between £20,000 andTable 3 Results of incremental economic analysis
Treatment Mean Cost Mean QALYs
At 10 years











Dom’d, dominated (Treatment costs more and is less effective than the other interv
more effective intervention); ICER, incremental cost-effectiveness ratio; QALY, qualit
aCompared with the next most effective strategy (excluding the extendedly domina
bCompared with the next most effective strategy (excluding the extendedly domina£30,000 per QALY gained, the probability that etanercept
was the preferred option was between 62% and 70% [19].
A limitation of any meta-analysis is the underlying as-
sumption that trials and outcomes are sufficiently similar
to allow data to be pooled. This applies to any method
of data synthesis, not just NMA. There is a relative pau-
city of data for both conventional and biological
DMARDs [51] which limits the number of studies avail-
able for the meta-analysis. This reduces the capacity for
a meta-analysis to estimate study heterogeneity. As there
were few studies that qualified for inclusion, common-
effects models were used in the meta-analysis in Rodgers
et al., 2011 [16] since these models provided a good fit
based on the deviation information criterion (DIC) out-
put from WinBUGs, as well as good convergence with-
out autocorrelation issues. In this analysis, with the
addition of one extra study, the models were found to
have good fit based on DIC, but also based on average
posterior mean residual deviance.
The lack of data meant we were unable to conduct a for-
mal investigation of potential sources of study heteroge-
neity. The treatment effect estimates may be affected by
potentially non-comparable populations, e.g. different se-
verity of disease, different patterns of disease, different
duration of disease, or by the use of different background
treatments, as well as differences in study design and
in the objective measurement of efficacy outcomes. In
particular the Outcome Measures in Rheumatology
(OMERACT) core set of domains are not consistently re-
ported in all RCTs reporting on treatments for PsA [51,52].
Although development of a validated, disease-specific com-
posite measure incorporating appropriate disease domains
into a single measure remains challenging [53], novelInc. Cost Inc. QALY ICER ICER v Conventional
- - - -
£23,484 0.7 Ext Dom’d £31,830
£6,920 0.2 Dom’d £33,178
£29,115 1.0 £28,917 £28,917
£11,308 0.1 £86,499 £35,534
- - - -
£25,941 1.5 Ext Dom’d £17,222
£7,629 0.4 Dom’d £17,435
£32,171 2.0 £16,426a £16,426
£12,799 0.2 £62,527b £20,789
ention); Ext Dom’d, extendedly dominated (ICER is greater than that of the
y-adjusted life years.
ted and dominated options) i.e. conventional management strategy.
ted and dominated options) i.e. etanercept.
Figure 2 Results from 1,000 model simulations. Upper panel: incremental cost and QALYs for etanercept plotted on cost-effectiveness plane;
lower panel: percentage of simulations where treatment has highest net monetary benefit at varying WTP thresholds.
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http://www.biomedcentral.com/1471-2474/15/26composite measures have recently been proposed to assess
disease activity in patients with PsA [54]. Trials should in-
corporate objective, measurable and relevant outcomes
though it remains to be determined which outcomes are of
most importance to patients.
The model outlined here is a replication of previous
models that has included the biologic golimumab, in
addition to etanercept, infliximab and adalimumab. How-
ever, the model has expanded the impact of the psoriasis
element of the disease by including PASI 50 and PASI 90
as well as PASI 75 scores which affect the estimation
of quality of life utility scores via the mapping algo-
rithm. The results of this model show that under base-
case assumptions, etanercept would be considered the
most cost-effective strategy for patients with PsA and
minimal, mild-to-moderate or moderate-to-severe skin
involvement. This result is fairly robust as the prob-
ability of etanercept being cost-effective at a WTP thres-
hold of £30,000 per QALY is 70%. This result is similar
to those produced in the early model versions that
excluded golimumab [16,17] and confirms the results
from a real-world study where TNF-α inhibitors were re-
ported to be cost-effective in the treatment of PsA patients
inadequately managed with conventional agents [55].Conclusions
In these selected studies, all bDMARDs were signifi-
cantly more effective than placebo in achieving PsARC
response in patients with active PsA. Across the studies
included in the analysis, etanercept and infliximab were
significantly more effective than placebo in improving
HAQ scores in all patients regardless of PsARC response
and in subgroups who achieved a PsARC response and
PsARC non-responders. The probabilistic analysis from
the model showed that, with a £30,000 per QALY WTP
threshold, etanercept is a cost-effective treatment for pa-
tients with active PsA compared with the other biologic
treatments of infliximab, adalimumab and golimumab
and also compared with the conventional management
strategy.Additional files
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